Michael Andrew Chambers - 04 Jun 2026 Form 4 Insider Report for Sarepta Therapeutics, Inc. (SRPT)

Reporting relationship: Director
Issuer ticker: SRPT
Reported as of: 04 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Jun 2026, 20:02:04 UTC
Prior SEC filing: 19 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Cristin L. Rothfuss, as Attorney-in-Fact for Michael Chambers

Key filing fact

Michael Andrew Chambers filed Form 4 for Sarepta Therapeutics, Inc. (SRPT) on 05 Jun 2026.

Key facts

This page summarizes Michael Andrew Chambers's Form 4 filing for Sarepta Therapeutics, Inc. (SRPT).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 05 Jun 2026, 20:02.

Change

Previous filing in this sequence was filed on 19 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001932527 Primary reporting owner

Chambers Michael Andrew

Relationship: Director
Address: 215 FIRST STREET, SUITE 415, CAMBRIDGE
Signature: /s/ Cristin L. Rothfuss, as Attorney-in-Fact for Michael Chambers
Signature date: 05 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SRPT transaction

Common Stock

Award

Transaction value
Shares: +16,875
Change %: +158%
Price
Shares after: 27,535
Date: 04 Jun 2026
Ownership: Direct
Footnotes: F1

SRPT holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 476,492
Date: 04 Jun 2026
Ownership: By Revocable Trust

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest on earlier of the one-year anniversary of the date of grant and the next annual meeting of stockholders which is at least 50 weeks after the immediately preceding year's annual meeting.